Bevacizumab plus irinotecan in treatment of recurrent brain gliomas

Rafał Stec; Lubomir Bodnar; Marta Smoter; Cezary Szczylik

doi:10.5114/wo.2010.14433

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2010
vol. 14

Send email

Copy url:

abstract:

Review paper

Bevacizumab plus irinotecan in treatment of recurrent brain gliomas

Rafał Stec

,

Lubomir Bodnar

,

Marta Smoter

,

Cezary Szczylik

Współczesna Onkologia (2010) vol. 14;4 (253-358)

DOI: https://doi.org/10.5114/wo.2010.14433

Online publish date: 2010/09/09

View full text Get citation

PlumX metrics:

Malignant gliomas including WHO grade III and grade IV tumours are a rare neoplasm (0.5% to 1% of all cancers). No standard therapy is available in the case of disease recurrence. In this review we assess the available literature evaluating the effect of chemoimmunotherapy based on bevacizumab and irinotecan in patients with recurrent WHO grade III and IV gliomas. Malignant gliomas are highly vascular and often express abundant amounts of vascular endothelial growth factor (VEGF). Neoplastic progression is dependent on angiogenesis, and anti-VEGF therapy has been successful in multiple disease states. Bevacizumab is a humanized monoclonal antibody that binds to and inhibits the activity of VEGF. Bevacizumab combined with irinotecan, an inhibitor of topoisomerase I, with good penetration to the CNS, appears to improve 6-month progression-free survival by 29% to 55%.
Conclusion: Bevacizumab in combination with irinotecan could be an active regimen for patients with recurrent WHO grade III and grade IV gliomas.

keywords:

Bevacizumab plus irinotecan in treatment of recurrent brain gliomas

Rafał Stec , Lubomir Bodnar , Marta Smoter , Cezary Szczylik

bevacizumab, irinotecan, gliomas grade III and IV

Rafał Stec

,

Lubomir Bodnar

,

Marta Smoter

,

Cezary Szczylik